![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Instituto de Olhos de Goiania |
---|---|
Information provided by: | Instituto de Olhos de Goiania |
ClinicalTrials.gov Identifier: | NCT00797992 |
To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
Condition | Intervention | Phase |
---|---|---|
Myopic Choroidal Neovascularization |
Drug: Injection |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Bevacizumab Intravitreal for Myopic Choroidal Neovascularization |
Enrollment: | 5 |
Study Start Date: | January 2007 |
Study Completion Date: | November 2008 |
Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Myopic eyes with retinal neovascularization
|
Drug: Injection
Intravitreal injection of 1.25 mg bevacizumab
|
Nineteen consecutive patients (19 eyes) with subfoveal PM-CNV, 18 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 1.25 mg bevacizumab or 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months.
Ages Eligible for Study: | 21 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | JN-05-2008-AR |
Study First Received: | November 24, 2008 |
Last Updated: | November 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00797992 |
Health Authority: | Brazil: National Health Surveillance Agency |
Bevacizumab Myopia Complications Neovascularization OCT |
Eye Diseases Metaplasia Choroid Diseases Bevacizumab |
Neovascularization, Pathologic Myopia Choroidal Neovascularization |
Uveal Diseases Pathologic Processes Antineoplastic Agents Therapeutic Uses Growth Substances |
Physiological Effects of Drugs Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |